Handelen Pfizer Inc - PFE CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.16 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.006402% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | -0.005927% | ||||||||
| Tijd van overnight-tarief | 22:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Pfizer Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 44.18 |
| Open* | 44.18 |
| 1-Jaarlijkse Verandering* | -17.5% |
| Dagelijks bereik* | 43.88 - 44.31 |
| 52 wekelijks bereik | 41.45-56.32 |
| Weekgemiddelde volume (10 dagen) | 28.04M |
| Gemiddeld volume (3 maanden) | 449.46M |
| Marktkapitalisatie | 248.89B |
| P/E Ratio | 8.10 |
| Uitstaande Aandelen | 5.61B |
| Omzet | 100.33B |
| EPS | 5.47 |
| Dividend (opbrengst %) | 3.69869 |
| Beta | 0.61 |
| Volgende inkomsten datum | May 1, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Feb 3, 2023 | 44.27 | 0.00 | 0.00% | 44.27 | 44.33 | 44.27 |
| Feb 2, 2023 | 44.26 | 0.25 | 0.57% | 44.01 | 44.44 | 43.47 |
| Feb 1, 2023 | 44.01 | -0.20 | -0.45% | 44.21 | 44.24 | 43.39 |
| Jan 31, 2023 | 44.21 | 0.72 | 1.66% | 43.49 | 44.25 | 41.79 |
| Jan 30, 2023 | 43.49 | -0.11 | -0.25% | 43.60 | 44.11 | 43.29 |
| Jan 27, 2023 | 43.71 | -0.43 | -0.97% | 44.14 | 44.32 | 43.45 |
| Jan 26, 2023 | 44.14 | -1.00 | -2.22% | 45.14 | 45.19 | 43.60 |
| Jan 25, 2023 | 45.01 | 0.31 | 0.69% | 44.70 | 45.15 | 44.49 |
| Jan 24, 2023 | 44.71 | -0.26 | -0.58% | 44.97 | 45.01 | 43.99 |
| Jan 23, 2023 | 44.97 | -0.11 | -0.24% | 45.08 | 45.29 | 44.57 |
| Jan 20, 2023 | 44.99 | 0.00 | 0.00% | 44.99 | 45.41 | 44.70 |
| Jan 19, 2023 | 44.98 | 0.00 | 0.00% | 44.98 | 45.24 | 44.52 |
| Jan 18, 2023 | 45.04 | -1.00 | -2.17% | 46.04 | 46.28 | 44.92 |
| Jan 17, 2023 | 46.04 | -1.07 | -2.27% | 47.11 | 47.29 | 45.70 |
| Jan 13, 2023 | 47.72 | 0.10 | 0.21% | 47.62 | 48.13 | 46.99 |
| Jan 12, 2023 | 47.62 | 0.26 | 0.55% | 47.36 | 47.71 | 46.56 |
| Jan 11, 2023 | 47.36 | -0.28 | -0.59% | 47.64 | 47.80 | 46.81 |
| Jan 10, 2023 | 47.64 | -0.72 | -1.49% | 48.36 | 48.59 | 47.36 |
| Jan 9, 2023 | 48.39 | -2.28 | -4.50% | 50.67 | 50.70 | 48.27 |
| Jan 6, 2023 | 50.89 | 1.31 | 2.64% | 49.58 | 51.56 | 49.54 |
Pfizer Inc Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, February 6, 2023 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2022 Pfizer Inc Earnings Release Q4 2022 Pfizer Inc Earnings ReleaseForecast -Previous - |
| Friday, April 28, 2023 | ||
| Time (UTC) 13:00 | Country US
| Event Pfizer Inc Annual Shareholders Meeting Pfizer Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, May 1, 2023 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2023 Pfizer Inc Earnings Release Q1 2023 Pfizer Inc Earnings ReleaseForecast -Previous - |
| Thursday, May 18, 2023 | ||
| Time (UTC) 10:59 | Country IN
| Event Q4 2023 Pfizer Ltd Earnings Release Q4 2023 Pfizer Ltd Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totale inkomsten | 52824 | 52546 | 40825 | 41172 | 41651 | 81288 |
| Inkomsten | 52824 | 52546 | 40825 | 41172 | 41651 | 81288 |
| Kosten van opbrengsten, totaal | 11925 | 10838 | 8872 | 8043 | 8405 | 30688 |
| Brutowinst | 40899 | 41708 | 31953 | 33129 | 33246 | 50600 |
| Totale bedrijfskosten | 43820 | 39557 | 36763 | 28841 | 33839 | 57636 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 14837 | 14784 | 12419 | 12485 | 11402 | 12256 |
| Onderzoek & Ontwikkeling | 7872 | 7657 | 7713 | 7731 | 9340 | 11582 |
| Depreciation / Amortization | 4056 | 4758 | 4736 | 4462 | 3348 | 3700 |
| Ongebruikelijke uitgaven (inkomsten) | 6058 | 2594 | 4675 | -2914 | 2619 | 3897 |
| Other Operating Expenses, Total | -928 | -1074 | -1652 | -966 | -1275 | -4487 |
| Bedrijfsresultaat | 9004 | 12989 | 4062 | 12331 | 7812 | 23652 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -824 | -972 | -538 | -877 | -538 | 560 |
| Gain (Loss) on Sale of Assets | 171 | 288 | 71 | 32 | -237 | 99 |
| Netto inkomen voor belastingen | 8351 | 12305 | 3594 | 11485 | 7036 | 24311 |
| Netto inkomen na belastingen | 7228 | 11954 | 3264 | 10545 | 6666 | 22459 |
| Minderheidsbelang | -31 | -47 | -36 | -29 | -36 | -45 |
| Netto inkomen voor extra. Posten | 7197 | 11907 | 3228 | 10516 | 6630 | 22414 |
| Totale buitengewone posten | 17 | 9402 | 7924 | 5757 | 2529 | -434 |
| Netto inkomen | 7214 | 21309 | 11152 | 16273 | 9159 | 21980 |
| Total Adjustments to Net Income | 0 | -2 | 0 | -1 | 0 | -1 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 7197 | 11905 | 3228 | 10515 | 6630 | 22413 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 7214 | 21307 | 11152 | 16272 | 9159 | 21979 |
| Verwaterd Netto Inkomen | 7214 | 21307 | 11152 | 16272 | 9159 | 21979 |
| Verwaterd Gewogen Gemiddelde Aandelen | 6159 | 6058 | 5977 | 5675 | 5632 | 5708 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 1.16853 | 1.96517 | 0.54007 | 1.85286 | 1.1772 | 3.92659 |
| Dividends per Share - Common Stock Primary Issue | 1.2 | 1.28 | 1.36 | 1.44 | 1.52 | 1.56 |
| Verwaterde Genormaliseerde Winst per Aandeel | 2.10748 | 2.31727 | 1.04885 | 1.22837 | 1.45366 | 4.09303 |
| Overige, Netto | -1 | -1 | -1 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 14516 | 18977 | 24094 | 23635 | 25661 |
| Inkomsten | 14516 | 18977 | 24094 | 23635 | 25661 |
| Kosten van opbrengsten, totaal | 4187 | 6986 | 9925 | 9611 | 10010 |
| Brutowinst | 10329 | 11991 | 14169 | 14024 | 15651 |
| Totale bedrijfskosten | 8989 | 13063 | 16447 | 19059 | 15788 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 2901 | 2794 | 2733 | 4069 | 2691 |
| Onderzoek & Ontwikkeling | 2010 | 2270 | 2738 | 4565 | 2655 |
| Depreciation / Amortization | 858 | 931 | 981 | 916 | 835 |
| Ongebruikelijke uitgaven (inkomsten) | -25 | 754 | 1613 | 1283 | 122 |
| Other Operating Expenses, Total | -942 | -672 | -1543 | -1385 | -525 |
| Bedrijfsresultaat | 5527 | 5914 | 7647 | 4576 | 9873 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 127 | 637 | 190 | -394 | -823 |
| Gain (Loss) on Sale of Assets | 39 | 58 | 1 | 0 | 1 |
| Overige, Netto | -1 | -2 | 1 | -1 | |
| Netto inkomen voor belastingen | 5692 | 6609 | 7836 | 4183 | 9050 |
| Netto inkomen na belastingen | 4884 | 5566 | 8167 | 3849 | 7878 |
| Minderheidsbelang | -9 | -26 | -12 | 2 | -6 |
| Netto inkomen voor extra. Posten | 4875 | 5540 | 8155 | 3851 | 7872 |
| Totale buitengewone posten | 1 | 24 | -9 | -458 | -9 |
| Netto inkomen | 4876 | 5564 | 8146 | 3393 | 7863 |
| Total Adjustments to Net Income | 1 | -1 | 1 | ||
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 4876 | 5539 | 8155 | 3851 | 7873 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 4877 | 5563 | 8146 | 3393 | 7864 |
| Verwaterd Netto Inkomen | 4877 | 5563 | 8146 | 3393 | 7864 |
| Verwaterd Gewogen Gemiddelde Aandelen | 5662 | 5678 | 5725 | 5768 | 5758 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 0.86118 | 0.97552 | 1.42445 | 0.66765 | 1.36732 |
| Dividends per Share - Common Stock Primary Issue | 0.39 | 0.39 | 0.39 | 0.39 | 0.4 |
| Verwaterde Genormaliseerde Winst per Aandeel | 0.82179 | 1.06851 | 1.40629 | 0.74896 | 1.31052 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totaal vlottende activa | 38949 | 41141 | 49926 | 32803 | 35067 | 59693 |
| Geldmiddelen en kortetermijnbeleggingen | 17850 | 19992 | 18833 | 9646 | 12221 | 31069 |
| Geldmiddelen & Equivalenten | 2595 | 1342 | 1139 | 1121 | 1784 | 1944 |
| Korte Termijn Investeringen | 15255 | 18650 | 17694 | 8525 | 10437 | 29125 |
| Totale Vorderingen, Netto | 8225 | 8221 | 8025 | 6772 | 7930 | 11479 |
| Accounts Receivable - Trade, Net | 8225 | 8221 | 8025 | 6772 | 7930 | 11479 |
| Total Inventory | 6783 | 7578 | 7508 | 7068 | 8046 | 9059 |
| Other Current Assets, Total | 6091 | 5350 | 15560 | 9317 | 6870 | 8086 |
| Total Assets | 171615 | 171797 | 159422 | 167594 | 154229 | 181476 |
| Property/Plant/Equipment, Total - Net | 13318 | 13865 | 13385 | 14258 | 15293 | 17721 |
| Property/Plant/Equipment, Total - Gross | 28125 | 30037 | 29977 | 29248 | 30104 | 32794 |
| Accumulated Depreciation, Total | -14807 | -16172 | -16591 | -14990 | -14812 | -15074 |
| Goodwill, Net | 54449 | 55952 | 53411 | 48202 | 49577 | 49208 |
| Intangibles, Net | 52648 | 48741 | 35211 | 33936 | 28471 | 25146 |
| Long Term Investments | 7116 | 7015 | 2767 | 20147 | 20262 | 21526 |
| Other Long Term Assets, Total | 5135 | 5083 | 4722 | 18248 | 5559 | 8182 |
| Total Current Liabilities | 31115 | 30427 | 31858 | 37304 | 25920 | 42671 |
| Accounts Payable | 4536 | 4656 | 4674 | 3887 | 4309 | 5578 |
| Accrued Expenses | 2487 | 2196 | 2397 | 2659 | 3379 | 3781 |
| Notes Payable/Short Term Debt | 6463 | 6407 | 4055 | 14733 | 701 | 605 |
| Current Port. of LT Debt/Capital Leases | 4225 | 3546 | 4776 | 1462 | 2002 | 1636 |
| Other Current Liabilities, Total | 13404 | 13622 | 15956 | 14563 | 15529 | 31071 |
| Total Liabilities | 112071 | 100489 | 96015 | 104450 | 90991 | 104276 |
| Total Long Term Debt | 31398 | 33538 | 32909 | 35955 | 37133 | 36195 |
| Long Term Debt | 31398 | 33538 | 32909 | 35955 | 37133 | 36195 |
| Deferred Income Tax | 30753 | 3900 | 3700 | 5652 | 4063 | 349 |
| Minority Interest | 296 | 348 | 351 | 303 | 235 | 262 |
| Other Liabilities, Total | 18509 | 32276 | 27197 | 25236 | 23640 | 24799 |
| Total Equity | 59544 | 71308 | 63407 | 63144 | 63238 | 77200 |
| Preferred Stock - Non Redeemable, Net | 24 | 21 | 19 | 17 | 0 | |
| Common Stock | 461 | 464 | 467 | 468 | 470 | 473 |
| Additional Paid-In Capital | 82685 | 84278 | 86253 | 87428 | 88674 | 90591 |
| Retained Earnings (Accumulated Deficit) | 71774 | 85291 | 89554 | 97670 | 96770 | 103394 |
| Treasury Stock - Common | -84364 | -89425 | -101610 | -110801 | -110988 | -111361 |
| Unrealized Gain (Loss) | -131 | 401 | -68 | -35 | 116 | -220 |
| Other Equity, Total | -10905 | -9722 | -11208 | -11603 | -11804 | -5677 |
| Total Liabilities & Shareholders’ Equity | 171615 | 171797 | 159422 | 167594 | 154229 | 181476 |
| Total Common Shares Outstanding | 6070 | 5979 | 5717 | 5534 | 5567 | 5620 |
| Total Preferred Shares Outstanding | 0.0006 | 0.00052 | 0.00048 | 0.00043 | 0 | 0 |
| Apr 2021 | Jul 2021 | Oct 2021 | Dec 2021 | Apr 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 39533 | 48814 | 57900 | 59693 | 54420 |
| Geldmiddelen en kortetermijnbeleggingen | 13667 | 21700 | 29696 | 31069 | 23897 |
| Geldmiddelen & Equivalenten | 1768 | 2372 | 1966 | 1944 | 2470 |
| Korte Termijn Investeringen | 11899 | 19328 | 27730 | 29125 | 21427 |
| Totale Vorderingen, Netto | 9864 | 10587 | 11897 | 11479 | 13225 |
| Accounts Receivable - Trade, Net | 9864 | 10587 | 11897 | 11479 | 13225 |
| Total Inventory | 8493 | 8948 | 8640 | 9059 | 9979 |
| Other Current Assets, Total | 7509 | 7579 | 7667 | 8086 | 7319 |
| Total Assets | 158818 | 169920 | 179188 | 181476 | 183841 |
| Property/Plant/Equipment, Total - Net | 14011 | 14224 | 14436 | 14882 | 15109 |
| Property/Plant/Equipment, Total - Gross | 29116 | 29552 | 29839 | 29955 | 30467 |
| Accumulated Depreciation, Total | -15105 | -15328 | -15403 | -15074 | -15358 |
| Goodwill, Net | 49791 | 49867 | 49489 | 49208 | 50211 |
| Intangibles, Net | 27974 | 27323 | 26306 | 25146 | 29816 |
| Long Term Investments | 20228 | 20942 | 21597 | 21526 | 20737 |
| Other Long Term Assets, Total | 7281 | 8750 | 9460 | 11021 | 13548 |
| Total Current Liabilities | 26652 | 35664 | 41803 | 42671 | 39268 |
| Accounts Payable | 4064 | 4327 | 4698 | 5578 | 5506 |
| Accrued Expenses | 1985 | 2015 | 2571 | 3332 | 2249 |
| Notes Payable/Short Term Debt | 676 | 201 | 966 | 605 | 385 |
| Current Port. of LT Debt/Capital Leases | 3676 | 3687 | 2663 | 1636 | 260 |
| Other Current Liabilities, Total | 16251 | 25434 | 30905 | 31520 | 30868 |
| Total Liabilities | 90198 | 99878 | 103496 | 104276 | 101417 |
| Total Long Term Debt | 35347 | 35354 | 36250 | 36195 | 35656 |
| Long Term Debt | 35347 | 35354 | 36250 | 36195 | 35656 |
| Deferred Income Tax | 4355 | 4161 | 328 | 349 | 655 |
| Minority Interest | 245 | 273 | 275 | 262 | 261 |
| Other Liabilities, Total | 23599 | 24426 | 24840 | 24799 | 25577 |
| Total Equity | 68620 | 70042 | 75692 | 77200 | 82424 |
| Common Stock | 472 | 472 | 473 | 473 | 476 |
| Additional Paid-In Capital | 89002 | 89336 | 89973 | 90591 | 90844 |
| Retained Earnings (Accumulated Deficit) | 95158 | 96346 | 102252 | 103394 | 111193 |
| Treasury Stock - Common | -111349 | -111356 | -111359 | -111361 | -113931 |
| Unrealized Gain (Loss) | -26 | 79 | -146 | -220 | -133 |
| Other Equity, Total | -4637 | -4835 | -5501 | -5677 | -6025 |
| Total Liabilities & Shareholders’ Equity | 158818 | 169920 | 179188 | 181476 | 183841 |
| Total Common Shares Outstanding | 5594 | 5599 | 5611 | 5620 | 5591 |
| Total Preferred Shares Outstanding | 0 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | 7246 | 21355 | 11188 | 16302 | 9652 | 22025 |
| Geldmiddelen uit Operationele Activiteiten | 16193 | 16802 | 15827 | 12587 | 14403 | 32580 |
| Geldmiddelen uit Operationele Activiteiten | 5757 | 6269 | 6384 | 6010 | 4777 | 5191 |
| Deferred Taxes | -700 | -2410 | -2205 | 614 | -1468 | -4293 |
| Niet-Geldelijke Posten | 3791 | -9748 | 1387 | -6307 | 1717 | -3147 |
| Cash Taxes Paid | 2521 | 2489 | 3655 | 3664 | 3153 | 7427 |
| Contant Betaalde Rente | 1451 | 1518 | 1311 | 1587 | 1641 | 1467 |
| Veranderingen in het Operationeel Kapitaal | 99 | 1336 | -927 | -4032 | -275 | 12804 |
| Geldmiddelen uit Investeringsactiviteiten | -7791 | -4740 | 4525 | -3945 | -4271 | -22546 |
| Kapitaaluitgaven | -1999 | -2217 | -2196 | -2594 | -2791 | -2711 |
| Overige Cash Flow investeringsposten, Totaal | -5792 | -2523 | 6721 | -1351 | -1480 | -19835 |
| Geldmiddelen uit Financieringsactiviteiten | -9228 | -13350 | -20441 | -8485 | -9649 | -9816 |
| Financiering van Cash Flow Posten | -536 | -612 | -589 | -735 | 11121 | 16 |
| Total Cash Dividends Paid | -7317 | -7659 | -7978 | -8043 | -8440 | -8729 |
| Uitgifte (Aflossing) van aandelen, netto | -3981 | -4138 | -10939 | -8471 | 425 | 0 |
| Uitgifte (Aflossing) van Schulden, Netto | 2606 | -941 | -935 | 8764 | -12755 | -1103 |
| Wisselkoerseffecten | -215 | 53 | -116 | -32 | -8 | -59 |
| Nettowijziging in Geldmiddelen | -1041 | -1235 | -205 | 125 | 475 | 159 |
| Apr 2021 | Jul 2021 | Oct 2021 | Dec 2021 | Apr 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 4886 | 10475 | 18633 | 22025 | 7870 |
| Cash From Operating Activities | 4539 | 15836 | 26666 | 32580 | 6541 |
| Cash From Operating Activities | 1226 | 2554 | 3914 | 5191 | 1187 |
| Deferred Taxes | 199 | -3702 | -4293 | -2321 | |
| Non-Cash Items | -446 | -1590 | -2997 | -3147 | 537 |
| Cash Taxes Paid | 394 | 2188 | 2943 | 7427 | 354 |
| Cash Interest Paid | 445 | 798 | 1205 | 1467 | 453 |
| Changes in Working Capital | -1326 | 4397 | 10818 | 12804 | -732 |
| Cash From Investing Activities | -1747 | -9884 | -19960 | -22546 | 567 |
| Capital Expenditures | -554 | -1094 | -1718 | -2711 | -643 |
| Other Investing Cash Flow Items, Total | -1193 | -8790 | -18242 | -19835 | 1210 |
| Cash From Financing Activities | -2807 | -5364 | -6465 | -9816 | -6578 |
| Financing Cash Flow Items | -610 | -510 | -185 | 16 | -500 |
| Total Cash Dividends Paid | -2172 | -4355 | -6540 | -8729 | -2249 |
| Issuance (Retirement) of Debt, Net | -25 | -499 | 260 | -1103 | -1829 |
| Foreign Exchange Effects | 0 | 5 | -32 | -59 | -1 |
| Net Change in Cash | -15 | 593 | 209 | 159 | 529 |
| Issuance (Retirement) of Stock, Net | 0 | -2000 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.7471 | 491001204 | 5107541 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.1238 | 287612741 | 395713 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.0984 | 286187374 | 1836743 | 2022-09-30 | LOW |
| Capital World Investors | Investment Advisor | 4.4332 | 248850529 | -1276218 | 2022-09-30 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 3.7567 | 210874152 | -8297495 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9675 | 110442140 | 1859302 | 2022-09-30 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 1.2492 | 70123906 | 6001894 | 2022-09-30 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0112 | 56763604 | 200794 | 2021-12-31 | LOW |
| Capital International Investors | Investment Advisor | 0.9856 | 55323878 | 5892896 | 2022-09-30 | LOW |
| State Farm Insurance Companies | Insurance Company | 0.9543 | 53568997 | 0 | 2022-09-30 | LOW |
| BofA Global Research (US) | Research Firm | 0.803 | 45074753 | -582392 | 2022-09-30 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7631 | 42832953 | -453753 | 2022-09-30 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7449 | 41814509 | -977163 | 2022-09-30 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.7363 | 41330356 | 393541 | 2022-09-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7347 | 41242414 | 1009399 | 2022-09-30 | LOW |
| MFS Investment Management | Investment Advisor/Hedge Fund | 0.7287 | 40906577 | -874608 | 2022-09-30 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.6492 | 36441408 | 1403401 | 2022-09-30 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.632 | 35478928 | -2969100 | 2022-09-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 0.5195 | 29162770 | -5775440 | 2022-09-30 | LOW |
| Mellon Investments Corporation | Investment Advisor/Hedge Fund | 0.5151 | 28915413 | -87396 | 2022-09-30 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group +485000+
Handelaren
65000+
Actieve klanten per maand
$48000000+
Maandelijks beleggingsvolume
$28000000+
Probeer het nu Opgenomen per maand
Handelscalculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Handelscommissie
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Hefboom
20:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Pfizer Company profile
Over Pfizer Inc
Pfizer Inc. (Pfizer) is een op onderzoek gebaseerde, wereldwijde biofarmaceutische onderneming. De onderneming houdt zich bezig met het ontdekken, ontwikkelen, produceren, op de markt brengen, verkopen en distribueren van biofarmaceutische producten. Haar wereldwijde portefeuille omvat geneesmiddelen en vaccins. Het bedrijf biedt therapeutische kandidaten in gastro-enterologie, dermatologie en cardiologie, waaronder etrasimod, een orale, selectieve sfingosine-1-fosfaat (S1P)-receptormodulator die in ontwikkeling is voor een reeks immuno-inflammatoire ziekten, waaronder colitis ulcerosa, de ziekte van Crohn, atopische dermatitis, eosinofiele esofagitis en alopecia areata. Het bedrijf werkt op verschillende markten aan de ontwikkeling van welzijn, preventie, behandelingen en genezing. Het werkt samen met zorgverleners, overheden en lokale gemeenschappen om gezondheidszorg te ondersteunen en toegankelijk te maken. De geneesmiddelen en vaccins van het bedrijf bieden waarde aan zorgverleners en patiënten, door behandeling van ziekten, verbetering van de gezondheid, welzijn.
| Industry: | Pharmaceuticals (NEC) |
235 E 42nd St
NEW YORK
NEW YORK 10017
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 485.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen